The TM-Flow System in Endocrinology: 4 Essential Applications for Metabolic Health

The intersection of TM-Flow endocrinology applications is creating new opportunities for metabolic disease management. By integrating autonomic and vascular measurements into endocrine practice workflows, physicians gain objective data that supports the evaluation of cardiovascular complications in at-risk and symptomatic patients.

Endocrinologists manage conditions like diabetes, thyroid disorders, and metabolic syndrome that carry significant cardiovascular risk. The TM-Flow System provides a non-invasive, point-of-care diagnostic platform that bridges the gap between metabolic assessment and vascular testing, helping endocrinology practices identify autonomic dysfunction and peripheral vascular compromise in at-risk patients.

Why TM-Flow Endocrinology Integration Matters

Patients with Type 2 diabetes face a two-to-four-fold increased risk of peripheral artery disease (PAD), and more than 30 percent of people with diabetes have autonomic neuropathy, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Traditional office-based exams often miss early-stage vascular and autonomic changes because they rely on subjective symptom reports and insensitive clinical tests like the monofilament exam.

The TM-Flow System addresses this gap by combining three FDA-cleared tests in a single 7 to 10 minute session:

• Ankle-Brachial Index (ABI) with pulse-volume recording for peripheral circulation assessment
• Photoplethysmography (PPG) for arterial stiffness and endothelial function evaluation
• Heart rate variability (HRV) analysis for autonomic nervous system assessment

This combination gives endocrinologists a comprehensive cardiovascular risk profile from a single, non-invasive encounter — data that would otherwise require multiple specialist referrals and separate appointments.

Four Key Applications for Endocrinology Practices

1. Objective Diabetic Neuropathy Testing

The TM-Flow sudomotor function test measures sweat gland innervation through galvanic skin response, assessing small-fiber nerve function earlier than traditional nerve conduction studies. Small-fiber involvement often precedes the large-fiber damage that conventional testing identifies, meaning endocrinologists can catch neuropathy progression at a stage where intervention — tighter glycemic control, medication adjustment, or neuroprotective strategies — can still prevent irreversible damage.

For diabetic patients, early sudomotor abnormalities correlate with higher cardiometabolic risk and predict progression to clinical neuropathy. Identifying these patients proactively enables endocrinologists to document medical necessity for intensified management and justify more frequent follow-up visits.

2. Cardiovascular Risk Stratification

By measuring arterial stiffness and autonomic balance simultaneously, the TM-Flow System identifies patients at elevated cardiovascular risk even when standard labs like HbA1c and lipid panels appear within acceptable ranges. Arterial stiffness — measured through PPG waveform analysis — reflects vascular aging and endothelial dysfunction that precede atherosclerotic plaque formation.

HRV analysis reveals shifts in sympathetic-parasympathetic balance that indicate cardiac autonomic neuropathy (CAN), a condition that is common in long-standing diabetes and independently increases the risk of sudden cardiac death. The published literature demonstrates that CAN is frequently undiagnosed because it progresses silently until patients develop resting tachycardia or orthostatic hypotension.

3. Metabolic Syndrome Monitoring

Serial TM-Flow testing provides objective, quantifiable data to track how lifestyle modifications, medication changes, or weight management programs affect vascular health over time. Unlike lab values that may take months to shift, vascular and autonomic metrics can show measurable changes within weeks of intervention.

For endocrinologists managing metabolic syndrome patients, this longitudinal tracking provides several clinical advantages: it motivates patient adherence through visual trend data, documents treatment response for insurance justification, and identifies patients whose metabolic interventions are not translating into cardiovascular improvement — a signal to escalate treatment intensity.

4. Thyroid-Cardiovascular Connection Assessment

Thyroid dysfunction directly impacts cardiovascular function. Hypothyroidism accelerates atherosclerosis through lipid metabolism changes and increased arterial stiffness, while hyperthyroidism can trigger atrial fibrillation and cardiac autonomic imbalance. The TM-Flow System allows endocrinologists to objectively measure these cardiovascular effects during thyroid management visits, providing data that supports treatment decisions around thyroid hormone dosing and cardiovascular co-management.

Reimbursement and Workflow Integration

TM-Flow testing maps to established CPT codes including 93923 (non-invasive vascular study), 95921 (autonomic function testing), and 95923 (sudomotor testing). For endocrinology practices already managing complex metabolic patients, the TM-Flow System adds diagnostic depth without adding significant chair time.

A medical assistant applies the cuffs and sensors, initiates the automated protocol, and the device completes all three tests in approximately 7 to 10 minutes. The physician reviews a color-coded summary report during the patient encounter, using the objective data to inform treatment decisions and document medical necessity. Results integrate into standard EHR workflows and provide structured documentation that supports referral decisions, prior authorization requests, and quality measure reporting for value-based care contracts.

Practices implementing TM-Flow testing in endocrinology workflows can improve diagnostic accuracy for their most complex patients by adding objective autonomic and vascular assessment to the clinical workflow. The key is identifying which patients benefit most — those with diabetes duration exceeding five years, metabolic syndrome with multiple risk factors, or thyroid conditions with suspected cardiovascular involvement.

Getting Started With TM-Flow in Your Endocrinology Practice

The TM-Flow System is available through HealthWright Technologies, which includes the device, staff training, billing guidance, and ongoing clinical support. Most practices achieve staff competency within a 90-minute certification session, and the automated testing protocol ensures consistent results regardless of operator experience.

For endocrinology practices considering adoption, the critical first step is identifying your high-risk patient cohort — typically 20-30% of your diabetic panel — and implementing a testing protocol for visits where indications are documented. This focused approach builds clinical experience and reimbursement history before expanding to broader patient populations.

CPT codes are provided for informational purposes only and do not guarantee reimbursement. Verify code applicability and coverage with the relevant payer and your billing department before submitting claims. CPT® is a registered trademark of the American Medical Association.

Ready to get started? Contact HealthWright Technologies to learn how the TM-Flow System supports your endocrinology practice with the device, training, and ongoing support — backed by our 90-day buyback: bill the CMAT Advantage tests correctly and compliantly, and if Medicare does not reimburse them, we buy the system back.

Frequently Asked Questions

How does the TM-Flow System benefit endocrinology practices?

The TM-Flow System provides endocrinologists with non-invasive, point-of-care autonomic and vascular diagnostics in a single 7 to 10 minute session. It characterizes small-fiber and autonomic function that traditional nerve conduction studies miss, stratifies cardiovascular risk through arterial stiffness measurement, and monitors metabolic syndrome progression with objective data, all billable under established CPT codes.

What CPT codes apply to TM-Flow testing in endocrinology?

TM-Flow testing maps to three established CPT codes: 93923 for non-invasive vascular studies (ABI/PVR), 95921 for autonomic function testing (HRV analysis), and 95923 for sudomotor testing. CPT codes are provided for informational purposes only, providers should verify coverage with individual payers before submitting claims.

Can the TM-Flow System add objective data when evaluating for diabetic neuropathy?

Yes. The TM-Flow sudomotor function test measures sweat gland innervation to assess small-fiber nerve function, which is relevant in patients at risk for neuropathy. Objective testing allows endocrinologists to intervene with tighter glycemic control and neuroprotective strategies before irreversible nerve damage occurs.

How does TM-Flow testing integrate into endocrinology office workflows?

A medical assistant applies the cuffs and sensors, starts the device, and the automated 7 to 10 minute protocol runs three simultaneous tests. The report is generated on the system in the office and can be printed or saved to the chart during the same encounter, and the physician reviews a color-coded report during the visit. Total added chair time is approximately 3 minutes beyond routine vitals.